Vera Therapeutics Inc

Latest Results (13.06.2024):

Q1 2024 Net Loss

For the quarter ended March 31, 2024, Vera Therapeutics Inc reported a net loss of $28.4 million, or a net loss per diluted share of $0.56. This compares to a net loss of $30.1 million, or a net loss per diluted share of $0.80, for the same period last year. This indicates a slight improvement in the company's financial performance compared to the previous year.

Q1 2024 Cash Usage

During the first quarter of 2024, Vera Therapeutics Inc used $33.8 million in net cash for operating activities. This is an increase from the $26.3 million used in the same quarter of the previous year, reflecting higher operational activities as the company advances its clinical programs.

Q1 2024 Cash Reserves

As of March 31, 2024, Vera Therapeutics Inc reported having $403.7 million in cash, cash equivalents, and marketable securities. This substantial reserve is believed to be sufficient to fund the company's operations through the anticipated approval and commercial launch of their lead product candidate, atacicept.

Q1 2024 R&D and G&A Expenses

Research and development expenses for Vera Therapeutics Inc in the first quarter of 2024 were $23.2 million, down from $25.1 million in the same quarter of the previous year. General and administrative expenses were $7.9 million, up from $6.2 million. This reflects the company's continued investment in its development activities while also managing its administrative responsibilities.

Q1 2024 Comprehensive Loss

The comprehensive loss for Vera Therapeutics Inc for the quarter ending March 31, 2024, was $28.8 million, compared to a comprehensive loss of $29.8 million for the same period last year. This includes all unrealized gains and losses and reflects a slight improvement in the company's overall financial health.